These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

121 related items for PubMed ID: 20398626

  • 1. Potent antitumor activities of recombinant human PDCD5 protein in combination with chemotherapy drugs in K562 cells.
    Shi L, Song Q, Zhang Y, Lou Y, Wang Y, Tian L, Zheng Y, Ma D, Ke X, Wang Y.
    Biochem Biophys Res Commun; 2010 May 28; 396(2):224-30. PubMed ID: 20398626
    [Abstract] [Full Text] [Related]

  • 2. Recombinant human PDCD5 sensitizes chondrosarcomas to cisplatin chemotherapy in vitro and in vivo.
    Chen C, Zhou H, Xu L, Xu D, Wang Y, Zhang Y, Liu X, Liu Z, Ma D, Ma Q, Chen Y.
    Apoptosis; 2010 Jul 28; 15(7):805-13. PubMed ID: 20349137
    [Abstract] [Full Text] [Related]

  • 3. Adenovirus-mediated PDCD5 gene transfer sensitizes K562 cells to apoptosis induced by idarubicin in vitro and in vivo.
    Ruan GR, Zhao HS, Chang Y, Li JL, Qin YZ, Liu YR, Chen SS, Huang XJ.
    Apoptosis; 2008 May 28; 13(5):641-8. PubMed ID: 18401719
    [Abstract] [Full Text] [Related]

  • 4. A novel triple-regulated oncolytic adenovirus carrying PDCD5 gene exerts potent antitumor efficacy on common human leukemic cell lines.
    Xie M, Niu JH, Chang Y, Qian QJ, Wu HP, Li LF, Zhang Y, Li JL, Huang XJ, Ruan GR.
    Apoptosis; 2009 Sep 28; 14(9):1086-94. PubMed ID: 19551515
    [Abstract] [Full Text] [Related]

  • 5. Recombinant human PDCD5 protein enhances chemosensitivity of breast cancer in vitro and in vivo.
    Wang L, Wang C, Su B, Song Q, Zhang Y, Luo Y, Li Q, Tan W, Ma D, Wang L.
    Biochem Cell Biol; 2013 Dec 28; 91(6):526-31. PubMed ID: 24219296
    [Abstract] [Full Text] [Related]

  • 6. Transfection of PDCD5 sensitizes colorectal cancer cells to cisplatin-induced apoptosis in vitro and in vivo.
    Yin A, Jiang Y, Zhang X, Zhao J, Luo H.
    Eur J Pharmacol; 2010 Dec 15; 649(1-3):120-6. PubMed ID: 20869960
    [Abstract] [Full Text] [Related]

  • 7. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice.
    Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, Frost P, Ye F, Boschelli DH, Boschelli F.
    Cancer Res; 2003 Jan 15; 63(2):375-81. PubMed ID: 12543790
    [Abstract] [Full Text] [Related]

  • 8. Triptolide inhibits Bcr-Abl transcription and induces apoptosis in STI571-resistant chronic myelogenous leukemia cells harboring T315I mutation.
    Shi X, Jin Y, Cheng C, Zhang H, Zou W, Zheng Q, Lu Z, Chen Q, Lai Y, Pan J.
    Clin Cancer Res; 2009 Mar 01; 15(5):1686-97. PubMed ID: 19240172
    [Abstract] [Full Text] [Related]

  • 9. Anti-tumor activity of emodin against human chronic myelocytic leukemia K562 cell lines in vitro and in vivo.
    Chun-Guang W, Jun-Qing Y, Bei-Zhong L, Dan-Ting J, Chong W, Liang Z, Dan Z, Yan W.
    Eur J Pharmacol; 2010 Feb 10; 627(1-3):33-41. PubMed ID: 19857484
    [Abstract] [Full Text] [Related]

  • 10. Antitumor effects of celecoxib on K562 leukemia cells are mediated by cell-cycle arrest, caspase-3 activation, and downregulation of Cox-2 expression and are synergistic with hydroxyurea or imatinib.
    Zhang GS, Liu DS, Dai CW, Li RJ.
    Am J Hematol; 2006 Apr 10; 81(4):242-55. PubMed ID: 16550520
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Design, synthesis, and biological evaluation of novel water-soluble triptolide derivatives: Antineoplastic activity against imatinib-resistant CML cells bearing T315I mutant Bcr-Abl.
    Xu F, Shi X, Li S, Cui J, Lu Z, Jin Y, Lin Y, Pang J, Pan J.
    Bioorg Med Chem; 2010 Mar 01; 18(5):1806-15. PubMed ID: 20149665
    [Abstract] [Full Text] [Related]

  • 13. Targeted RNA interference of cyclin A2 mediated by functionalized single-walled carbon nanotubes induces proliferation arrest and apoptosis in chronic myelogenous leukemia K562 cells.
    Wang X, Ren J, Qu X.
    ChemMedChem; 2008 Jun 01; 3(6):940-5. PubMed ID: 18286553
    [Abstract] [Full Text] [Related]

  • 14. [Effect of ZGDHu-1 on proliferation and apoptosis of A549 cells in vitro and antitumor activity in vivo].
    Zhou YL, Hu WX, Lü YP, Qiu LN, Wang WS, Yang ZY, Liu JD, Rao GW.
    Yao Xue Xue Bao; 2007 Jan 01; 42(1):26-34. PubMed ID: 17520803
    [Abstract] [Full Text] [Related]

  • 15. Disruption of the inhibitor of apoptosis protein survivin sensitizes Bcr-abl-positive cells to STI571-induced apoptosis.
    Wang Z, Sampath J, Fukuda S, Pelus LM.
    Cancer Res; 2005 Sep 15; 65(18):8224-32. PubMed ID: 16166298
    [Abstract] [Full Text] [Related]

  • 16. Abnormal expression of the programmed cell death 5 gene in acute and chronic myeloid leukemia.
    Ruan GR, Qin YZ, Chen SS, Li JL, Ma X, Chang Y, Wang YZ, Fu JY, Liu YR.
    Leuk Res; 2006 Sep 15; 30(9):1159-65. PubMed ID: 16507320
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. In vitro and in vivo study of cell growth inhibition of simvastatin on chronic myelogenous leukemia cells.
    Yang YC, Huang WF, Chuan LM, Xiao DW, Zeng YL, Zhou DA, Xu GQ, Liu W, Huang B, Hu Q.
    Chemotherapy; 2008 Sep 15; 54(6):438-46. PubMed ID: 18824851
    [Abstract] [Full Text] [Related]

  • 19. Glucocorticoid cotreatment induces apoptosis resistance toward cancer therapy in carcinomas.
    Herr I, Ucur E, Herzer K, Okouoyo S, Ridder R, Krammer PH, von Knebel Doeberitz M, Debatin KM.
    Cancer Res; 2003 Jun 15; 63(12):3112-20. PubMed ID: 12810637
    [Abstract] [Full Text] [Related]

  • 20. Comparison of antitumor effect of recombinant L-asparaginase with wild type one in vitro and in vivo.
    Guo QL, Wu MS, Chen Z.
    Acta Pharmacol Sin; 2002 Oct 15; 23(10):946-51. PubMed ID: 12370101
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.